Clinical Trial of Ilidar, a New Dibenzazepine Adrenergic Blocking Drug, in the Treatment of Peripheral Vascular Diseases and Miscellaneous Complaints
Ilidar, a new adrenergic blocking drug, has been administered to 116 patients; follow-up was adequate on 86. The drug was highly effective in patients with predominantly vasospastic disorders and in patients with postphlebetic syndrome, and moderately effective in patients with thromboangiitis and arteriosclerosis. Most patients could tolerate 50 to 75 mg. three to four times a day. Side effects were principally those to be expected from the moderate postural hypotension associated with effective sympathetic blockade, namely, weakness, dizziness, nausea.
- © 1954 American Heart Association, Inc.